Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Okumura, Yasuhiro ^a   Yamamoto, Yutaka ^a   Zhang, Zhenhuan ^a   Toyama, Tatsuya ^b   Kawasoe, Teru ^a   Ibusuki, Mutsuko ^a   Honda, Yumi ^c   Iyama, Ken Ichi ^c   Yamashita, Hiroko ^b   Iwase, Hirotaka ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FACTOR; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; SURVIVIN; APOPTOSIS REGULATORY PROTEIN; TUMOR MARKER;

ADULT; AGED; ANTIBODY LABELING; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CONTROLLED STUDY; DISEASE COURSE; DUCTAL CARCINOMA IN SITU; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NICK END LABELING; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR NECROSIS; ANALYSIS OF VARIANCE; BREAST TUMOR; CELL PROLIFERATION; CHEMISTRY; CHI SQUARE DISTRIBUTION; FEMALE; MIDDLE AGED; NONPARAMETRIC TEST; PAGET NIPPLE DISEASE; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL PROLIFERATION; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MIDDLE AGED; NEOPLASM INVASIVENESS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 54149091790     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-287     Document Type: Article

References (34)

1. Page DL Dupont WD Rogers LW Landenberger M Intraductal carcinoma of the breast: Follow-up after biopsy only Cancer 1982, 49(4):751-758. 10.1002/ 1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y 6275978
2. Tsikitis VL Chung MA Biology of ductal carcinoma in situ classification based on biologic potential Am J Clin Oncol 2006, 29(3):305-310. 10.1097/ 01.coc.0000198740.33617.2f 16755185
3. Page DL Dupont WD Rogers LW Jensen RA Schuyler PA Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy Cancer 1995, 76(7):1197-1200. 10.1002/ 1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0 8630897
4. Tang P Hajdu SI Lyman GH Ductal carcinoma in situ: A review of recent advances Curr Opin Obstet Gynecol 2007, 19(1):63-67. 17218854
5. Greene FL Page DL Fleming ID Haga T Staging Manual Philadelphia: Lippincott-Raven; 6 2002.
6. Silver SA Tavassoli FA Mammary ductal carcinoma in situ with microinvasion Cancer 1998, 82(12):2382-2390. 10.1002/ (SICI)1097-0142(19980615)82:12<2382::AID-CNCR12>3.0.CO;2-L 9635531
7. Adamovich TL Simmons RM Ductal carcinoma in situ with microinvasion Am J Surg 2003, 186(2):112-116. 10.1016/S0002-9610(03)00166-1 12885600
8. Cavaliere A Scheibel M Bellezza G Colella R Vitali R Gori S Aristei C Rulli A Sidoni A Ductal carcinoma in situ with microinvasion: clinicopathologic study and biopathologic profile Pathol Res Pract 2006, 202(3):131-135. 10.1016/j.prp.2006.01.001 16459026
9. Bijker N Peterse JL Duchateau L Robanus-Maandag EC Bosch CA Duval C Pilotti S Vijver van de MJ Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ Br J Cancer 2001, 84(4):539-544. 10.1054/bjoc.2000.1618 11207051
10. Kerlikowske K Molinaro A Cha I Ljung BM Ernster VL Stewart K Chew K Moore DH 2nd Waldman F Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy J Natl Cancer Inst 2003, 95(22):1692-1702. 14625260
11. Provenzano E Hopper JL Giles GG Marr G Venter DJ Armes JE Histological markers that predict clinical recurrence in ductal carcinoma in situ of the breast: An Australian population-based study Pathology 2004, 36(3):221-229. 10.1080/00313020410001692558 15203725
12. Barnes DM Bartkova J Camplejohn RS Gullick WJ Smith PJ Millis RR Overexpression of the c-erbB-2 oncoprotein: Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer 1992, 28:2-3. 10.1016/S0959-8049(05)80117-0 1567667
13. Bobrow LG Happerfield LC Gregory WM Springall RD Millis RR The classification of ductal carcinoma in situ and its association with biological markers Semin Diagn Pathol 1994, 11(3):199-207. 7831531
14. Leal CB Schmitt FC Bento MJ Maia NC Lopes CS Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein Cancer 1995, 75(8):2123-2131. 10.1002/ 1097-0142(19950415)75:8<2123::AID-CNCR2820750815>3.0.CO;2-V 7697603
15. Iwase H Ando Y Ichihara S Toyoshima S Nakamura T Karamatsu S Ito Y Yamashita H Toyama T Omoto Y et al. Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast Breast Cancer 2001, 8(2):98-104. 10.1007/BF02967487 11342981
16. Roka S Rudas M Taucher S Dubsky P Bachleitner-Hofmann T Kandioler D Gnant M Jakesz R High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS Eur J Surg Oncol 2004, 30(3):243-247. 10.1016/j.ejso.2003.11.004 15028303
17. Zhao YG Xiao AZ Park HI Newcomer RG Yan M Man TG Heffelfinger SC Sang QY Endometase/Matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinases-2 and -4: A putative role in the initiation of breast cancer invasion Cancer Research 2004, 64(2):590-598. 10.1158/0008-5472.CAN-03-1932 14744773
18. Tamm I Wang Y Sausville E Scudiero DA Vigna N Oltersdorf T Reed JC IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs Cancer Res 1998, 58(23):5315-5320. 9850056
19. Kennedy SM O'Driscoll L Purcell R Fitz-Simons N McDermott EW Hill AD O'Higgins NJ Parkinson M Linehan R Clynes M Prognostic importance of survivin in breast cancer Br J Cancer 2003, 88(7):1077-1083. 10.1038/ sj.bjc.6600776 12671708
20. Kayaselcuk F Nursal TZ Polat A Noyan T Yildirim S Tarim A Seydioglu G Expression of survivin, bcl-2, P53 and bax in breast carcinoma and ductal intraepithelial neoplasia (DIN 1a) J Exp Clin Cancer Res 2004, 23(1):105-112. 15149158
21. Barnes N Haywood P Flint P Knox WF Bundred NJ Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence Br J Cancer 2006, 94(2):253-258. 10.1038/sj.bjc.6602932 16421596
22. Silverstein MJ Poller DN Waisman JR Colburn WJ Barth A Gierson ED Lewinsky B Gamagami P Slamon DJ Prognostic classification of breast ductal carcinoma-in-situ Lancet 1995, 345:1154-1157. 10.1016/ S0140-6736(95)90982-6 7723550
23. Monteagudo C Merino MJ San-Juan J Liotta LA Stetler-Stevenson WG Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue Am J Pathol 1990, 136(3):585-592. 1877499 2156430
24. Al-Joudi F Iskandar Z Hasnan J Rusli J Kamal Y Imran A Ahmed M Zakaria J Expression of survivin and its clinicopathological correlations in invasive ductal carcinoma of the breast Singapore Med J 2007, 48(7):607-614. 17609820
25. Yamamoto Y Ibusuki M Okumura Y Kawasoe T Kai K Iyama K Iwase H Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer Breast Cancer Res Treat 2008, 110(3):465-75. 10.1007/s10549-007-9742-1 17805961
26. Kobayashi S Iwase H Ito Y Yamashita H Iwata H Yamashita T Ito K Toyama T Nakamura T Masaoka A Clinical significance of bcl-2 gene expression in human breast cancer tissues Breast Cancer Res Treat 1997, 42(2):173-181. 10.1023/A:1005760013810 9138606
27. Tanaka K Iwamoto S Gon G Nohara T Iwamoto M Tanigawa N Expression of survivin and its relationship to loss of apoptosis in breast carcinomas Clin Cancer Res 2000, 6(1):127-134. 10656440
28. Iwase H Omoto Y Iwata H Hara Y Ando Y Kobayashi S Genetic and epigenetic alterations of the estrogen receptor gene and hormone independence in human breast cancer Oncology 1998, 55(Suppl 1):11-16. 10.1159/000055254 9852397
29. Yamashita S Masuda Y Kurizaki T Haga Y Murayama T Ikei S Kamei M Takeno S Kawahara K Survivin expression predicts early recurrence in early-stage breast cancer Anticancer Res 2007, 27(4C):2803-2808. 17695451
30. Hinnis AR Luckett JC Walker RA Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients Br J Cancer 2007, 96(4):639-645. 10.1038/sj.bjc.6603616 17285125
31. Chu JS Shew JY Huang CS Immunohistochemical analysis of survivin expression in primary breast cancers J Formos Med Assoc 2004, 103(12):925-931. 15624042
32. Rehman S Crow J Revell PA Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers Pathol Oncol Res 2000, 6(4):256-263. 11173657
33. Kapucuoglu N Losi L Eusebi V Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive duct breast carcinomas Virchows Arch 1997, 430(1):17-22. 10.1007/BF01008011 9037310
34. Mommers EC van Diest PJ Leonhart AM Meijer CJ Baak JP Balance of cell proliferation and apoptosis in breast carcinogenesis Breast Cancer Res Treat 1999, 58(2):163-169. 10.1023/A:1006396103777 10674882